Oral Solid Dosage Pharmaceutical Formulation Market Future Trends Influencing Growth Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Oral Solid Dosage Pharmaceutical Formulation Market Grow Between 2026 And 2030?
The oral solid dosage pharmaceutical formulation market has seen significant expansion in recent years. It is projected to increase from $653.26 billion in 2025 to $692.14 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.0%. Historically, this market growth can be attributed to the broad acceptance of oral drug delivery, a well-established manufacturing infrastructure for tablets and capsules, the rising prevalence of chronic diseases, the cost-effectiveness of oral solid dosage forms, and strong regulatory familiarity with oral formulations.
The oral solid dosage pharmaceutical formulation market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a size of $846.38 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the projected period include a heightened demand for long-acting oral medications, an increasing emphasis on patient adherence and ease of use, the expansion of pharmaceutical outsourcing and Contract Development and Manufacturing Organization (CDMO) services, an increase in global generic drug manufacturing, and advancements in excipients and formulation technologies. Key trends anticipated during the forecast period involve a greater embrace of controlled and modified-release dosage forms, an escalating demand for patient-friendly oral solid formats, the expansion of both generic and branded solid dosage manufacturing, a heightened focus on formulations with high bioavailability, and a move towards more cost-effective and scalable oral dosage production methods.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
What Key Factors Are Affecting The Oral Solid Dosage Pharmaceutical Formulation Market Demand?
The escalating occurrence of chronic diseases is projected to stimulate the expansion of the oral solid dosage pharmaceutical formulation market in the future. These conditions are characterized as prolonged health issues that persist for an extended duration, typically exceeding three months. The increase in chronic diseases stems from factors such as aging populations, sedentary lifestyles, inadequate dietary habits, environmental influences, and enhanced detection and diagnosis methods. Oral solid dosage pharmaceutical formulations are vital for the effective management of chronic diseases, aiding long-term treatment adherence due to their convenience, stability, and precise dosing. Illustratively, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, marking a 77% rise compared to the estimated 20 million cases in 2022. Thus, the rising prevalence of chronic diseases is a key driver for the growth of the oral solid dosage pharmaceutical formulation market.
What Are The Different Segment Types In The Oral Solid Dosage Pharmaceutical Formulation Market Segment Breakdown?
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
What Emerging Trends Are Seen In The Oral Solid Dosage Pharmaceutical Formulation Market?
Leading companies within the Oral Solid Dosage (OSD) pharmaceutical market are concentrating on creating novel solutions like fixed dose combinations to boost effectiveness, patient adherence, and overall safety. A fixed dose combination (FDC) is a medication that includes two or more active drugs united in a single dosage form, aiming to streamline treatment and enhance patient consistency. For instance, in February 2025, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical entity, obtained approval from the U.S. Food and Drug Administration (FDA) for its Journavex (suzetrigine) 50 mg oral tablets, intended for managing moderate to severe acute pain in adults. This medication operates by specifically inhibiting NaV1.8 sodium channels in the peripheral nervous system, thereby blocking pain signals before their transmission to the brain, providing efficient pain relief without the dangers of addiction. Clinical trials demonstrated a notable decrease in pain levels when compared to a placebo, along with a well-tolerated safety profile that included minor adverse reactions such as itching and muscle spasms.
Who Are The Well-Known Companies In The Oral Solid Dosage Pharmaceutical Formulation Market?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Get The Full Oral Solid Dosage Pharmaceutical Formulation Market Report:
Which Region Is The Top Contributor To The Oral Solid Dosage Pharmaceutical Formulation Market By Share?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Oral Solid Dosage Pharmaceutical Formulation Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Oral Solid Dosage Pharmaceutical Formulation Market 2026, By The Business Research Company
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Oral Solid Dosage Contract Manufacturing Market Report 2026
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
